โ† All CNPR Flashcard Decks

Healthcare Industry Knowledge & Drug Approval Process Flashcards

9 cards from real CNPR practice questions. Tap to flip, then mark Knew It or Still Learning โ€” missed cards come back until you master them.

Read the first 9 Healthcare Industry Knowledge & Drug Approval Process flashcards as text
  1. What is the first phase of clinical drug trials?

    Answer: Phase I

    Phase I clinical trials are the first stage where an experimental drug is tested in humans, typically a small group of healthy volunteers. The primary goal of this phase is to assess the drug's safety, determine a safe dosage range, and identify any potential side effects. It focuses on how the drug is metabolized and excreted, rather than its effectiveness.

  2. Which U.S. agency is responsible for approving new drugs?

    Answer: FDA

    The U.S. Food and Drug Administration (FDA) is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. This includes rigorously reviewing and approving new drugs before they can be marketed and sold to the public. The FDA's approval process involves evaluating extensive data from clinical trials to ensure a drug's benefits outweigh its risks.

  3. What is the purpose of Phase III clinical trials?

    Answer: To compare with existing treatments and ensure effectiveness

    Phase III clinical trials are large-scale studies involving hundreds to thousands of patients, designed to confirm the drug's effectiveness and monitor side effects in a larger population. A key objective is to compare the new drug's efficacy and safety against existing standard treatments or a placebo. This phase provides the robust data needed to determine if the drug offers a significant clinical benefit and is safe enough for widespread use.

  4. What document is submitted to the FDA to begin clinical trials?

    Answer: IND

    An Investigational New Drug (IND) application is a submission to the FDA that must be filed and approved before any new drug can be tested in human clinical trials. This document details the drug's composition, manufacturing process, and results from preclinical (animal) studies, along with the proposed clinical trial protocols. The IND ensures that human subjects are not exposed to unreasonable risks during early drug development.

  5. Which phase focuses on long-term safety and effectiveness after approval?

    Answer: Phase IV

    Phase IV clinical trials, also known as post-marketing surveillance, occur after a drug has been approved by the FDA and is available to the public. This phase focuses on monitoring the drug's long-term safety and effectiveness in diverse, real-world populations. It helps identify rare side effects or long-term risks that may not have been apparent in earlier, smaller clinical trials.

  6. What is the NDA in the drug approval process?

    Answer: New Drug Application

    A New Drug Application (NDA) is a comprehensive document submitted to the FDA by a pharmaceutical company once all clinical trials (Phases I, II, and III) are complete. The NDA contains all scientific data and information about the drug, including its safety, efficacy, manufacturing, and labeling. The FDA reviews the NDA to decide whether to approve the drug for marketing in the U.S.

  7. Why is preclinical testing conducted before human trials?

    Answer: To assess safety before human exposure

    Preclinical testing involves in vitro (test tube) and in vivo (animal) studies conducted before any human trials begin. Its primary purpose is to gather crucial safety data and preliminary efficacy information about a new drug candidate. This helps determine if the drug is reasonably safe to proceed to human testing and to identify potential toxicities, protecting human volunteers from undue harm.

  8. Who oversees the drug approval process in the EU?

    Answer: EMA

    The European Medicines Agency (EMA) is the decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines developed for use in the EU. Similar to the FDA in the U.S., the EMA plays a central role in approving new drugs for the European market, ensuring they meet high standards of quality, safety, and efficacy.

  9. What is the role of the Institutional Review Board (IRB)?

    Answer: To ensure ethical conduct in human research

    An Institutional Review Board (IRB) is a committee formally designated to review and monitor biomedical and behavioral research involving human subjects. Its primary role is to protect the rights, welfare, and safety of research participants by ensuring that studies are ethically sound, risks are minimized, and informed consent is properly obtained. No human research can proceed without IRB approval.